Blue Horseshoe Stocks

News Alert, Trio of Fresh Options Ideas

Cannabis Bioscience International Holdings, Inc. (OTCMKTS:CBIH) – News Alert:

We’re circling back to CBIH this morning, a medical cannabis stock that was the focus of our Special Report last Tuesday. We suggest taking a look at that report if you missed it the first time. Today, the company has released some really exciting news regarding the appointment of Brian Cuban to its advisory board.

It further signifies CBIH’s movement in an extremely positive direction for 2024, and we are very eager to see what Mr. Cuban can do to assist in the company’s ambitious growth plans.
_____

BIG CBIH NEWS:

HOUSTON, TX–(Newsfile Corp. – February 26, 2024) – Cannabis Bioscience International Holdings (OTC Pink: CBIH) is excited to announce that Brian Cuban has been elected by our firm as an Advisory Board Member. Mr. Cuban will bring decades of experience in legal and corporate leadership, and a long track record of coaching diverse professionals around the world.

Brian Cuban, the younger brother of the former principal owner of the Dallas Mavericks, Mark Cuban, is an attorney, author, and mental health awareness and recovery advocate. He is a graduate of Penn State University and The University of Pittsburgh School of Law. Brian has been in long-term recovery from alcohol, cocaine, and bulimia since April of 2007. He is the author of the best-selling book, The Addicted Lawyer, Tales of The Bar, Booze Blow & Redemption. His debut novel, The Ambulance Chaser, was released as the #1 selling debut paperback thriller with a second, The Body Brokers, due to be published Christmas of 2024: www.briancuban.com (>>View Full PR)
_____

For more information on CBIH, please visit cbih.net
and/or contact Peter Nicosia at (585) 703-6565 with any inquiries.

Friday Runners Recap:

We fared quite well on Friday, despite the markets having a rough day and most of our ideas being bullish in nature. We included an array of five potential trading ideas in our premarket report, and each one of them exhibited some really nice intraday upswings. It concluded a fantastic week in which we only missed on one target the entire stretch.

Our focal points for Friday’s session were the NVDA Weekly $795-805 Calls, the SPY 02/23 $507-508 Calls, the SQ Weekly $77-79 Calls, the WBD Weekly $9.50-9.00 Puts and the LUNR 03/15 $10-12.50 Calls. Here were the moves they recorded on the day:

NVDA Weekly $795-805 Calls
$795: 1.66-11.13 (+570%)
$800: 1.17-7.53 (+544%)
$805: .77-4.88 (+534%)
_____

SPY 02/23 $507-508 Calls
$507: 1.10-2.16 (+96%)
$508: .63-1.38 (+119%)
_____

SQ Weekly $77-79 Calls
$77: 1.90-4.75 (+150%)
$78: 1.22-3.89 (+219%)
$79: .69-2.80 (+306%)
_____

WBD Weekly $9.50-9.00 Puts
$9.50: .67-1.32 (+97%)
$9.00: .30-.75 (+150%)
_____

LUNR 03/15 $10-12.50 Calls
$10: 1.70-3.10 (+82%)
$12.50: 1.20-2.20 (+83%)

Fresh Options Ideas:
PPC 03/15 $30-31 Calls
DPZ Weekly $455-465 Calls
LI Weekly $38-39 Calls

Extended Watchlist:
HOLO, ZVSA, ASTI, TRNR, FRGT, ADN, NHMD, OPTI, TPTW

Top Notch Thursday Runners, 5 New Targets

Nice Moves on Thursday:

It was another excellent session for us on Thursday, as we formulated a 4-pack of fresh options ideas in our premarket report for the day. Thanks in part to an exceptionally bullish session for the markets in general, all four of our tracked sets of calls made some significant intraday day upswings.

Our interests for the day included the MRNA Weekly $91-93 Calls, the TCOM 03/15 $44-45 Calls, the PANW Weekly $260-270 Calls, and the NVDA Weekly $755-765 Calls, and here were the types of daily gains that were up for grabs on those targets:

MRNA Weekly $91-93 Calls
$91: 2.23-10.15 (+355%)
$92: 2.06-9.53 (+362%)
$93: 1.41-8.67 (+514%)
_____

TCOM 03/15 $44-45 Calls
$44: 1.40-1.90 (+36%)
$45: .85-1.45 (+71%)
_____

PANW Weekly $260-270 Calls
$260: 7.78-15.50 (+99%)
$265: 4.61-12.00 (+160%)
$270: 2.48-7.68 (+210%)
_____

NVDA Weekly $755-765 Calls
$755: 10.80-31.50 (+192%)
$760: 9.26-27.00 (+192%)
$765: 7.82-22.65 (+190%)

Fresh Options Ideas:
NVDA Weekly $795-805 Calls*
SPY 02/23 $507-508 Calls*
SQ Weekly $77-79 Calls*
WBD Weekly $9.50-9.00 Puts*
LUNR 03/15 $10-12.50 Calls

*Only experienced traders should attempt to trade options contracts on their day of expiration

Extended Watchlist:
FTCHF, LEAS, STEV, ASTA, TBIO, OCEA, SUGP, ENVB,

Midweek Movers, 4 New Targets

Wednesday’s Options Runners:

We got things right back on track with respect to our daily options ideas yesterday. Our premarket report contained a slate of four potential plays, and we saw some really nice intraday movement in all four of them. We have been on an incredible streak in this regard for all of 2024 so far, and as always, we’ll be trying our hardest to sustain that trend to the best of our ability. We sincerely thank all of our long-time and new readers alike for the incredible daily engagement and read rates!

Yesterday’s fresh targets were the VRT Weekly $56-54 Puts, the GRMN 03/25 $130 Calls, the PANW Weekly $280-275 Puts, and the PSA 03/15 $290-300 Calls, and here were the largest intraday runs posted by each of them on the day:

VRT Weekly $56-54 Puts
$56: .31-1.20 (+287%)
$55: .15-.82 (+447%)
$54: .14-.55 (+293%)
_____

GRMN 03/25 $130 Calls
$130: 2.94-8.60 (+192%)
_____

PANW Weekly $280-275 Puts
$280: 12.20-20.30 (+66%)
$277.50: 10.59-17.15 (+62%)
$275: 8.80-16.18 (+84%)
_____

PSA 03/15 $290-300 Calls
$290: 4.30-5.64 (+31%)
$300: 3.50-5.01 (+43%)

Fresh Options Ideas:
MRNA Weekly $91-93 Calls
TCOM 03/15 $44-45 Calls
PANW Weekly $260-270 Calls
NVDA Weekly $755-765 Calls

Extended Watchlist:
MNPR, AGRX, VERO, BZFD, EAST, GMBL, TSPH, ASPU

Key Recaps, 4 Fresh Options Ideas

Recap of Friday’s Options Plays:

For those who took Monday’s break to relax and may have missed out on our relaying of Friday’s activity, we’re going to drop the recap of those plays one more time this morning. We didn’t do so yesterday of course, because we gave sole focus for the day to a special report on a new company that has engaged us for investor relations. We urge those who might have missed that report to click here and read it now.

As for our last active options ideas, here are those figures from Friday’s report one more time, and today we’ll do our best to generate some more good ideas today:

COIN Weekly $185-190
$185: 1.85-8.58 (+364%)
$190: .72-4.95 (+587%)
_____

MARA Weekly $27.50-28.50 Calls
$28: .09-.78 (+767%)
_____

TTD Weekly $87-89 Calls
$87: 1.01-3.66 (+264%)
$88: .76-2.83 (+272%)
$89: .54-2.03 (+276%)

Fresh Options Ideas:
VRT Weekly $56-54 Puts
GRMN 03/25 $130 Calls
PANW Weekly $280-275 Puts
PSA 03/15 $290-300 Calls

AgriFORCE Growing Systems Ltd. (NASDAQ:AGRI) – Recap:

We recently tagged AGRI on Feb. 9th, and caught the stock at a subsequent low of .20. Yesterday it registered a new high of .706, which equates to a respectable rise of 253% over the past couple of weeks.

It’s always pleasing to find NASDAQ plays that are making OTC level runs in such short periods of time, and another reason why it’s a good idea to pay as much attention to our extended watchlist plays as you do to our featured content!

Extended Watchlist:
IVP, SOGP, EFOI, GBNH, SEED, VCIG, MOTS, AABB, SHMP, CBIA, TONR

OTC Medical Cannabis Special Report

Cannabis Bioscience International Holdings, Inc. (OTCMKTS:CBIH) Special Report:

For today’s report, we’re excited to be profiling Cannabis Bioscience International Holdings (“CBIH“), an intriguing cannabis company that has its sights set on securing a piece of the massive global CBD (Cannabidiol) market. CBD is expected to enjoy a compound annual growth rate of nearly 50%, reaching a market valuation of over $55 billion by 2028 (according to cbih.net).

As we’ve recently mentioned, we’ve had loads of experience with OTC Cannabis stocks and we can recognize a good ground-floor opportunity when we see one. Right now, CBIH appears to have all the pieces in place to write a very compelling story in 2024 and beyond. CBIH has been hard at work developing multiple CBD-based treatments for osteoarthritis, anxiety, PTSD, and an array of other common physical and psychological afflictions, with the intention of running a full gamut of clinical trials to prove their effectiveness.

In a recent letter to shareholders (via Newsfile Corp), company CEO Dante Picazo communicated his excitement over one CBIH product in particular- Orthocann. It is his belief that it could become the world’s first intra-articular injection for the treatment of osteoarthritis, to actually help rebuild tissues which have been damaged by the disease. While certainly an intriguing prospect, it is also the company’s intent to market Orthocann as an ointment and a capsule as well.

According to Medical News Today, roughly half a billion people (~7% of the global population) suffer from this most common form of arthritis that primarily affects people over 40-50 years of age. That’s well over 30 million individuals in the US alone, which is obviously a huge market for CBIH to target with Orthocann. Considering that we are a country with a rapidly increasing elderly population, one would also expect those figures to climb higher by the year.

In addition to a full line of CBD formulations, CBIH is also in the business of medicinal cannabis education, offering tools to the public via Pharmacology University, an online learning platform to educate individuals on the chemistry, cultivation, and many benefits of, and opportunities presented by, cannabis and its byproducts. In this regard, we feel that CBIH is acting as an excellent ambassador for the medical cannabis industry at large.

Stay tuned for future updates on Cannabis Bioscience International Holdings, and its big plans for 2024.

NEW CBIH NEWS:

This morning, CBIH has officially announced its engagement of our parent company to help transform its approach to investor relations, and aid in bringing the company’s vision for the future to life. A charge that we take very seriously, and are honored to undertake.

HOUSTON, TX–(NewsFile Corp. – February 20, 2024) – Cannabis Bioscience International Holdings, a Houston-based company trading on the OTC Markets under the ticker symbol CBIH, has engaged the services of Bull in Advantage as its Investor Relations firm. (>>VIEW PR)

For more information on CBIH, please visit cbih.net
and/or contact Peter Nicosia at (585) 703-6565 with any inquiries.